Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study

Clinical trial NCT05096832 · COMPLETED

Trial details

NCT number: NCT05096832
Sponsor: Livzon Pharmaceutical Group Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

COVID-19 Pandemic

Start date: 2021-11-03
Primary completion: 2022-02-18
Enrollment: 10381

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.